Quantcast

Got Stocks from QualityStocks Ones To Watch

Got Stocks

Find out which Small-Cap / Micro-Caps should be on your radar. Get the news and information that moves the markets this week and the "Ones to Watch", only at QualityStocks. The "Quality" is Back in Stocks...




Untitled Document

SANUWAVE Health, Inc. (SNWV)

OTC BB-listed SANUWAVE Health, Inc. is a leading shock wave technology company. It focuses on the development and commercialization of patented non-invasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. SANUWAVE Health researches, designs, manufactures, markets and services its products worldwide. The company has its corporate office in Alpharetta, Georgia.

SANUWAVE Health's portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses. This produces new vascularization and microcirculatory improvement. This helps in restoring the body's normal healing processes and leads to regeneration of tissue.

There are license/partnership opportunities for SANUWAVE's shock wave technology for non-medical uses. This includes energy, water, food and industrial markets. SANUWAVE's intention is to apply its Pulsed Acoustic Cellular Expression (PACE®) technology in wound healing, orthopedic/spine, plastic/cosmetic, and cardiac conditions.

The company's lead product candidate for the worldwide wound care market, dermaPACE®, is CE marked across Europe. It has Canada, Australia, and New Zealand device license approval for the treatment of the skin and subcutaneous soft tissue. In the U.S., dermaPACE is now under the Food and Drug Administration's (FDA's) Premarket Approval (PMA) review process for the treatment of diabetic foot ulcers.

SANUWAVE's belief is that it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, and stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the use of its OssaTron®, Evotron® and orthoPACE® devices in Europe, Asia, and Asia/Pacific.

The company's principal emphasis remains gaining approval for its dermaPACE to treat diabetic foot ulcers. However, it continues to pursue additional applications, which also have potentially significant market opportunities. SANUWAVE's leading opportunities are in biofilm destruction and oil exploration and development. In oil exploration and development, it received a patent for use in the energy industry related to the use of shock waves, generated with laser systems, for hydraulic fracturing of rock formations, which can be utilized in secondary and tertiary oil recovery. This is the company's first patent for the energy industry.

 

 

 

The QualityStocks
Newsroom

Read the articles covering the biggest movers in the markets today.

Continue

Market
Basics

Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks markets.

Continue

The QualityStocks Daily
Archives

Go back to see our previous newsletters and find out what you might have missed.

Continue